Myocarditis associated with clozapine treatment [11]

Australian and New Zealand Journal of Psychiatry

Volumn 34, Issue 5, 2000, Pages 880-

  Degner, D ^a   Bleich, S ^a   Grohmann, R ^a   Bandelow, B ^a   Ruther, E ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGRANULOCYTOSIS; AUSTRALIA; CLINICAL FEATURE; COHORT ANALYSIS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; GENETIC SUSCEPTIBILITY; GERMANY; HOSPITAL PATIENT; HUMAN; HYPERTHERMIA; INCIDENCE; LETTER; MALE; MENTAL PATIENT; MYOCARDITIS; SCHIZOPHRENIA; SWITZERLAND; UNITED KINGDOM; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CLOZAPINE; HUMAN; INCIDENCE; MALE; MYOCARDITIS; SCHIZOPHRENIA;

EID: 0033813949     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2000.0822n.x     Document Type: Letter

References (5)

1. Myocarditis under therapy with clozapine
2. Myocarditis and cardiomyopathy associated with clozapine
3. Myocarditis with antipsychotics: Recent cases with clozapine (Clozaril)
4. Mortality in current and former users of clozapine
5. Assessment of adverse drug reactions in psychiatric inpatients with AMSP Drug Safety Program: Methods and first results for tricyclic antidepressants and SSRI